The effects of ocular surface disease on optical coherence tomography test results in patients with glaucoma

Abstract

Purpose:

To evaluate the effects of current ocular surface disease (OSD) on OCT signal quality and peripapillary retinal nerve fiber layer (RNFL) thickness measurements in patients treated with antiglaucomatous medications and the changes in these test results by dry eye treatment.

Methods:

Fifty-five patients, diagnosed with primary open-angle glaucoma (POAG) and OSD, who were treated for glaucoma with topical medications for at least 6 months were included in this study. Patients were treated with topical preservative free polyvinyl alcohol + povidone artificial tear drops four times a day for at least 20 days and topical loteprednol etabonate drops four times a day for 1 week. Patients were divided into groups according to the number of active substances in their glaucoma drops, daily drop numbers, and duration of drug utilizations. OCT signal quality and mean RNFL thickness measurements were evaluated within these groups before and after OSD treatment.

Results:

Pre-treatment mean OCT signal quality was 19.15 ± 3.739 and mean RNFL thickness was 93.07 ± 13.931µ; post-treatment mean OCT signal quality was 23.93 ± 3.839 and mean RNFL thickness was 98.27 ± 14.863 µ (p < 0.05). Post-treatment measurements were significantly improved compared to pre-treatment measurements in our patients, but the differences among subgroups were not statistically significant. There was a strong positive correlation between pre-treatment signal quality measurements and Schirmer II test values (p < 0.0001).

Conclusion:

Treatment of OSD in glaucoma patients being treated with long-term anti-glaucoma medications, seem to improve the quality and reliability of OCT test results.